A new George Church startup raises $16M. The first-time founders have a ‘crazy vision’ to bring ML to cell therapy
2023-09-21
细胞疗法
By her own admission, Elizabeth Wood is far from a typical biotech CEO.
Fittingly, she’s building an unconventional startup in JURA Bio, which announced on Thursday a $16.1 million seed round to bring machine learning into developing cell therapies. Wood co-founded JURA back in 2017 alongside Julie Norville, an MIT bioengineering PhD who is JURA’s chief technology officer.
The Harvard biologist George Church is also a founder, telling
Endpoints News
he expects JURA to play a role in an “amazing revolution” that applies machine learning to complex libraries of drug candidates. He says JURA is one of six biotechs he has founded around that theme. Others include
Shape Therapeutics
for RNA editing,
Dyno Therapeutics
on optimizing AAV vectors,
Nabla Bio
for designing antibodies, and
Manifold Bio
for protein therapeutics.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
-靶点
-药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。